Successful treatment of advanced ovarian cancer with anlotinib: a case report

Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor growth. Previous research demonstrated clinical antitumor activity of anlotinib in various cancers. We report the case of an elderly woman with advanced ovarian cancer who received anlotinib after failure of multiple-line chemotherapy. A partial response was observed after six cycles of anlotinib monotherapy, with a reduction in the size of the metastases and significantly decreased serum CA125 levels from 1832.7 U/mL to 118.7 U/mL. She continued to take anlotinib, with a progression-free survival time of more than 4 months. Only mild hypertension was observed during the treatment. Anlotinib monotherapy may be a novel therapeutic option for patients with advanced ovarian cancer.

[1]  B. Shan,et al.  Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study. , 2020, Journal of Clinical Oncology.

[2]  Xuan Zhang,et al.  Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer , 2020, Medicine.

[3]  Yongkun Sun,et al.  Anlotinib for advanced hepatocellular carcinoma: Interim results from the phase II ALTER0802 study , 2019, Annals of Oncology.

[4]  J. Song,et al.  Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203) , 2019, Annals of Oncology.

[5]  Y. Liu,et al.  Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC) , 2019, Annals of Oncology.

[6]  Hongxia Li,et al.  Knockdown of long non-coding RNA LINC00152 increases cisplatin sensitivity in ovarian cancer cells. , 2019, Experimental and therapeutic medicine.

[7]  Hong Song,et al.  Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia , 2019, AMB Express.

[8]  L. Tang,et al.  China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy , 2019, Cancer communications.

[9]  Ying Cheng,et al.  Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial. , 2019, Journal of Clinical Oncology.

[10]  Jingjing Zhang,et al.  Expression and clinical significance of SLP-2 in ovarian tumors , 2019, Oncology letters.

[11]  Jie He,et al.  Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial. , 2019, Journal of Clinical Oncology.

[12]  B. Han,et al.  Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy , 2018, European Respiratory Journal.

[13]  F. Du,et al.  Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development , 2018, Journal of Hematology & Oncology.

[14]  Li Lin,et al.  CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study , 2018, Cancer medicine.

[15]  K. Lisowska,et al.  Advances in ovarian cancer therapy , 2017, Cancer Chemotherapy and Pharmacology.

[16]  F. Du,et al.  Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors , 2016, Journal of Hematology & Oncology.

[17]  B. Monk,et al.  Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.